Articles from PlaqueTec

PlaqueTec, a medtech company pioneering intracoronary liquid biopsy to identify inflammatory drivers of cardiovascular disease (CVD), today announced it has raised $5 million. The oversubscribed financing round was funded entirely by the Company’s existing investor base.

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD. The trial has been designed to improve understanding of the pathobiology of atherosclerotic cardiovascular diseases (ACVD) and how it varies between individuals, to aid the development of novel therapies and treatment approaches.